<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183076</url>
  </required_header>
  <id_info>
    <org_study_id>F2016-1301-72</org_study_id>
    <nct_id>NCT03183076</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy</brief_title>
  <official_title>Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy in Adults Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Atkins Diet Modified (ADM) is the best alternative treatment for drug-resistant epilepsy,
      There is a high prevalence worldwide , especially in Latin American countries, including
      Mexico.

      Low income earners, many of which do not have a social security, must meet the high costs by
      Antiepileptic Drugs (AEDS), which in addition should be used in conjunction or combination
      therapy, because monotherapy is insufficient .

      The diet adkins makes some changes in the traditional food habits by others that are
      accessible and not necessarily expensive, whose mechanism allows for better control of the
      seizures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the efficacy, tolerability and adherence of the modified adkins diet in
      adult patients with drug-resistent epilepsy Materials and Methods: Clinical trial, made up of
      patients with drug-resistent epilepsy, selected by convenience, who will be handled
      pharmacologically with the standard treatment of this condition for a period of not less than
      6 months, after which they will be treated with adkins diet modified, prior informed consent,
      to establish its effect and a comparative analysis later.

      The objective of this work is to analyze the efficacy, tolerability and adherence of the
      modified atkins diet in adult patients with drug-resistant epilepsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">December 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical trial, Parallel, controled</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>MD María Ingrid Alanis Guevara. Neurologist Hospital of the Western National Medical Center. Guadalajara. Mexico</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of epileptic seizures</measure>
    <time_frame>3 months</time_frame>
    <description>Frequency of epileptic seizures measured according to the clinical criteria of therapeutic evaluation of Huttenlocher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic response observed in electroencephalogram</measure>
    <time_frame>3 months</time_frame>
    <description>Panic electroencephalographic criteria on the therapeutic response. Having regard to the standardization, improvement or worsening of the crisis in the electroencephalogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of quality of life and decrease in seizures</measure>
    <time_frame>3 months</time_frame>
    <description>Interrogate the patient with a questionnaire of refractory epilepsy drugs. And ask to the patient with this questionnaire if improved their quality of life and have decreased seizures after using the atkins diet modified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood tests (Hematic biometry)</measure>
    <time_frame>3 months</time_frame>
    <description>Take this blood test to assess the general conditions of the patient and see their levels of hemoglobin, hematocrit, leukocyte and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood chemistry (serum electrolytes)</measure>
    <time_frame>3 months</time_frame>
    <description>It will evaluate the general condition of the patient and with this test rule out the presence of electrolyte imbalance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function tests</measure>
    <time_frame>3 months</time_frame>
    <description>Will be evaluated with this test levels of transaminases as can be raised by treatment anticonvulsant and see if there are any changes with the changes in the diet of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ketonuria</measure>
    <time_frame>3 months</time_frame>
    <description>It will assess the levels of ketones in urine due to the change in the diet of patients with the Atkins diet</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Epilepsy, Drug Resistant</condition>
  <arm_group>
    <arm_group_label>modified adkins diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacotherapy without diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>modified adkins diet</intervention_name>
    <description>Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis</description>
    <arm_group_label>modified adkins diet</arm_group_label>
    <other_name>adkins diet in drug-resistant epilepsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacotherapy without diet</intervention_name>
    <description>Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet</description>
    <arm_group_label>Pharmacotherapy without diet</arm_group_label>
    <other_name>treatment with antiepileptic drugs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age of 18 years

          -  Patients that meet the criteria of drug-resistant epilepsy

          -  Patients treated with Rational polytherapy, a minimum of 6 months, with no changes in
             their drug refractory condition.

          -  Patients with drug- resistant epilepsy with informed consent signed by themselves and
             their proxy.

          -  Patients with drug-resistant epilepsy of any etiology, except tumor, metabolic,
             degenerative or progressive.

        Exclusion Criteria:

          -  Patients with drug-resistant epilepsy simultaneous alternate treatment to the Atkins
             Diet modified.

          -  Patients with a neurological entity progressive and fatal

          -  Patients with congenital diseases and difficulty to metabolize fats or that require
             high amounts of carbohydrates in the diet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María I Alanis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Medical Center, Mexican Institute of Social Security</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989 Jul-Aug;30(4):389-99.</citation>
    <PMID>2502382</PMID>
  </reference>
  <reference>
    <citation>Panico LR, Ríos VG, Demartini MG, Carniello MA. [The electroencephalographic evolution of a group of patients on a ketonic diet]. Rev Neurol. 2000 Jan 1-15;30(1):8-15. Spanish.</citation>
    <PMID>10742989</PMID>
  </reference>
  <reference>
    <citation>Freeman J, Veggiotti P, Lanzi G, Tagliabue A, Perucca E; Institute of Neurology IRCCS C. Mondino Foundation. The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res. 2006 Feb;68(2):145-80.</citation>
    <PMID>16523530</PMID>
  </reference>
  <reference>
    <citation>Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, Buchhalter JR, Caraballo RH, Helen Cross J, Dahlin MG, Donner EJ, Klepper J, Jehle RS, Kim HD, Christiana Liu YM, Nation J, Nordli DR Jr, Pfeifer HH, Rho JM, Stafstrom CE, Thiele EA, Turner Z, Wirrell EC, Wheless JW, Veggiotti P, Vining EP; Charlie Foundation, Practice Committee of the Child Neurology Society; Practice Committee of the Child Neurology Society; International Ketogenic Diet Study Group. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009 Feb;50(2):304-17. doi: 10.1111/j.1528-1167.2008.01765.x. Epub 2008 Sep 23.</citation>
    <PMID>18823325</PMID>
  </reference>
  <results_reference>
    <citation>Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia. 2006 Feb;47(2):431-6.</citation>
    <PMID>16499772</PMID>
  </results_reference>
  <results_reference>
    <citation>Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology. 2002 Apr 23;58(8 Suppl 5):S2-8.</citation>
    <PMID>11971127</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922.</citation>
    <PMID>19889013</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwan P, Brodie MJ. Definition of refractory epilepsy: defining the indefinable? Lancet Neurol. 2010 Jan;9(1):27-9. doi: 10.1016/S1474-4422(09)70304-7. Epub 2009 Nov 13.</citation>
    <PMID>19914135</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9.</citation>
    <PMID>10660394</PMID>
  </results_reference>
  <results_reference>
    <citation>Martínez-Juárez IE, López-Zapata R, Gómez-Arias B, Bravo-Armenta E, Romero-Ocampo L, Estévez-Cruz Z, Hernández-De la Cruz G, Morán-Molina S. [Refractory epilepsy: use of the new definition and related risk factors. A study in the Mexican population of a third-level centre]. Rev Neurol. 2012 Feb 1;54(3):159-66. Spanish.</citation>
    <PMID>22278892</PMID>
  </results_reference>
  <results_reference>
    <citation>Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia. 1996;37 Suppl 2:S1-S3. Review.</citation>
    <PMID>8641240</PMID>
  </results_reference>
  <results_reference>
    <citation>Devinsky O. Patients with refractory seizures. N Engl J Med. 1999 May 20;340(20):1565-70. Review.</citation>
    <PMID>10332020</PMID>
  </results_reference>
  <results_reference>
    <citation>Arroyo S. [Evaluation of drug-resistant epilepsy]. Rev Neurol. 2000 May 1-15;30(9):881-6. Review. Spanish.</citation>
    <PMID>10870204</PMID>
  </results_reference>
  <results_reference>
    <citation>Benbadis SR, Tatum WO, Vale FL. When drugs don't work: an algorithmic approach to medically intractable epilepsy. Neurology. 2000 Dec 26;55(12):1780-4. Review.</citation>
    <PMID>11188984</PMID>
  </results_reference>
  <results_reference>
    <citation>Hauser WA. The natural history of drug resistant epilepsy: epidemiologic considerations. Epilepsy Res Suppl. 1992;5:25-8. Review.</citation>
    <PMID>1418457</PMID>
  </results_reference>
  <results_reference>
    <citation>Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith DF, Tudur-Smith C, Vanoli A, Williamson PR. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134.</citation>
    <PMID>17903391</PMID>
  </results_reference>
  <results_reference>
    <citation>Sánchez-Alvarez JC, Serrano-Castro P, Cañadillas-Hidalgo F. [Refractory epilepsy in adults]. Rev Neurol. 2002 Nov 16-30;35(10):931-53. Review. Spanish.</citation>
    <PMID>12436398</PMID>
  </results_reference>
  <results_reference>
    <citation>Serrano Castro PJ, Sánchez Alvarez JC. [Controversies about the new anti-epileptic drugs]. Rev Neurol. 2001 Jan 16-31;32(2):165-71. Review. Spanish.</citation>
    <PMID>11299481</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomez-Alonso J, Giraldez BG. [Epilepsy: a new definition for an old disease]. Rev Neurol. 2007 Jul 16-31;45(2):126-7. Spanish.</citation>
    <PMID>17642053</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J Jr. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005 Apr;46(4):470-2.</citation>
    <PMID>15816939</PMID>
  </results_reference>
  <results_reference>
    <citation>Hefft S, Jonas P. Asynchronous GABA release generates long-lasting inhibition at a hippocampal interneuron-principal neuron synapse. Nat Neurosci. 2005 Oct;8(10):1319-28. Epub 2005 Sep 11.</citation>
    <PMID>16158066</PMID>
  </results_reference>
  <results_reference>
    <citation>Hestrin S, Galarreta M. Synchronous versus asynchronous transmitter release: a tale of two types of inhibitory neurons. Nat Neurosci. 2005 Oct;8(10):1283-4.</citation>
    <PMID>16189532</PMID>
  </results_reference>
  <results_reference>
    <citation>Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol. 2007 Oct;62(4):382-9.</citation>
    <PMID>17880009</PMID>
  </results_reference>
  <results_reference>
    <citation>Duncan JS. The outcome of epilepsy surgery. J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):432.</citation>
    <PMID>11254763</PMID>
  </results_reference>
  <results_reference>
    <citation>Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology. 1971 Nov;21(11):1097-103.</citation>
    <PMID>5166216</PMID>
  </results_reference>
  <results_reference>
    <citation>Panico LR, Demartini MG, Ríos VG, Carniello MA. [The ketogenic diet in infantile refractory epilepsy: electroclinical response, complications and secondary effects]. Rev Neurol. 2000 Aug 1-15;31(3):212-20. Spanish.</citation>
    <PMID>10996924</PMID>
  </results_reference>
  <results_reference>
    <citation>Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics. 2000 Apr;105(4):E46. Review.</citation>
    <PMID>10742367</PMID>
  </results_reference>
  <results_reference>
    <citation>Vicente-Hernández M, Garcia-Garcia P, Gil-Nagel A, Lopez-Munoz F, Alamo C. [Therapeutic approach to epilepsy from the nutritional view: current status of dietary treatment]. Neurologia. 2007 Oct;22(8):517-25. Review. Spanish.</citation>
    <PMID>17641989</PMID>
  </results_reference>
  <results_reference>
    <citation>Yudkoff M, Daikhin Y, Melø TM, Nissim I, Sonnewald U, Nissim I. The ketogenic diet and brain metabolism of amino acids: relationship to the anticonvulsant effect. Annu Rev Nutr. 2007;27:415-30. Review.</citation>
    <PMID>17444813</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>María Ingrid Alanis Guevara</investigator_full_name>
    <investigator_title>MD neurologist</investigator_title>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>Diet, Carbohydrate-Restricted</keyword>
  <keyword>Drug Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

